Related Experiment Videos
Fusidic acid in bone and joint infections.
1Department of Microbiology and Infectious Diseases, Concord Repatriation General Hospital, NSW, Australia.
International Journal of Antimicrobial Agents
|October 21, 1999
Summary
Fusidic acid (FA) shows promise for treating staphylococcal bone and joint infections, including osteomyelitis and septic arthritis. Further research is needed for methicillin-resistant Staphylococcus aureus strains.
Area of Science:
- Orthopaedic Infections
- Pharmacology
Background:
- Staphylococci are primary causes of bone and joint infections.
- Fusidic acid (FA) is a potential treatment option for these infections.
Purpose of the Study:
- To review the efficacy of fusidic acid (FA) in treating various orthopaedic infections caused by staphylococci.
Main Methods:
- Review of studies on FA in acute and chronic osteomyelitis, septic arthritis, and device-related infections.
- Analysis of studies using FA alone or in combination with other antimicrobials.
- Evaluation of local FA applications, such as in bone cement or plaster beads.
Main Results:
- FA demonstrates efficacy against susceptible Staphylococcus aureus in diverse orthopaedic infections.
- Studies show good outcomes with FA monotherapy and local applications.
- FA is effective in treating osteomyelitis, septic arthritis, and device-related infections.
Conclusions:
- Fusidic acid (FA) is effective for treating many staphylococcal orthopaedic infections.
- Local delivery methods for FA show promising results.
- More research is necessary to confirm FA's efficacy against methicillin-resistant Staphylococcus aureus (MRSA).